Outlook Therapeutics, Inc.
OTLK
$0.70
-$0.02-2.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 90.39% | -232.69% | -333.56% | -145.38% | 59.44% |
| Total Depreciation and Amortization | 4.47% | 4.51% | 3.13% | 2.44% | 3.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -124.72% | 129.65% | 91.18% | 109.71% | -62.94% |
| Change in Net Operating Assets | 191.36% | -134.35% | -22.73% | 222.82% | -369.62% |
| Cash from Operations | 52.80% | -36.21% | 27.12% | 39.01% | 13.93% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -48.64% | -- | -- | -- | -- |
| Total Debt Repaid | 48.34% | -- | -- | -- | -2,991,718.18% |
| Issuance of Common Stock | -62.19% | 791.50% | -- | 228.55% | -67.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -62.58% | 791.50% | 10,151.74% | 207.50% | -67.16% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -150.13% | 106.44% | 95.22% | 108.84% | -94.97% |